Siemens' blood test for fatty liver disease scores de novo clearance from FDA

Blood tests that can cover the entire liver are important, as NAFLD and NASH do not spread through the organ evenly. Despite being the current gold standard, a biopsy may miss advanced disease by taking tissue from the wrong area. (magicmine/Getty Images)

Though it is predicted to become a top cause of organ damage and liver transplants within this decade, treatments for nonalcoholic fatty liver disease, or NAFLD, have stalled for a simple reason: It can be hard to tell who has the condition and who does not.

Ref:https://www.fiercebiotech.com/medtech/siemens-blood-test-for-fatty-liver-disease-scores-de-novo-clearance-from-fda